{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:15:09Z","timestamp":1778058909423,"version":"3.51.4"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["DBT\/RA\/2023-24\/Call-II\/RA\/11"],"award-info":[{"award-number":["DBT\/RA\/2023-24\/Call-II\/RA\/11"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014824","name":"Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020582","name":"National Institute of Pharmaceutical Education and Research, Raebareli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bcp.2026.117754","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:19:50Z","timestamp":1769559590000},"page":"117754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Unmasking the role of tumor microenvironment in the advanced stage of cancer treatment to mitigate risks during chemotherapy"],"prefix":"10.1016","volume":"246","author":[{"given":"Anchala","family":"Kumari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niranjan","family":"Meher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Dey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurav","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubhini A.","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-4855","authenticated-orcid":false,"given":"Nidhi","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","article-title":"Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance","volume":"43","author":"Bhat","year":"2024","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41392-024-01955-5","article-title":"Multi-stage mechanisms of tumor metastasis and therapeutic strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","article-title":"Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2026.117754_b0020","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00018-024-05537-0","article-title":"HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects","volume":"82","author":"Shi","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0030","first-page":"167","article-title":"Tumour hypoxia in driving genomic instability and tumour evolution","volume":"25","author":"Suvac","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/cancers17030441","article-title":"Heterogeneity in cancer","volume":"17","author":"MacDonald","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","article-title":"Invasion and metastasis in cancer: molecular insights and therapeutic targets","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.117754_b0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.55544\/jrasb.2.6.26","article-title":"Targeted therapies in cancer treatment: unveiling the latest breakthroughs and promising approaches","volume":"2","author":"Rai","year":"2024","journal-title":"J. Res. Appl. Sci. Biotechnol."},{"issue":"312","key":"10.1016\/j.bcp.2026.117754_b0055","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1259\/0007-1285-26-312-638","article-title":"The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy","volume":"26","author":"Gray","year":"1953","journal-title":"Br. J. Radiol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0060","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/bjc.1955.55","article-title":"The histological structure of some human lung cancers and the possible implications for radiotherapy","volume":"9","author":"Thomlinson","year":"1955","journal-title":"Br. J. Cancer"},{"issue":"3191","key":"10.1016\/j.bcp.2026.117754_b0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.bcp.2026.117754_b0070","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.117754_b0075","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/0360-3016(86)90267-1","article-title":"SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells","volume":"12","author":"Zeman","year":"1986","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"13","key":"10.1016\/j.bcp.2026.117754_b0080","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1073\/pnas.88.13.5680","article-title":"Hypoxia-inducible nuclear factors bind to an enhancer element located 3'to the human erythropoietin gene","volume":"88","author":"Semenza","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2026.117754_b0085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4161\/cc.3.2.618","article-title":"Hypoxia inducible carbonic anhydrase IX, marker of tumour: hypoxia, survival pathway and therapy target","volume":"3","author":"Potter","year":"2004","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/157488406775268192","article-title":"Tirapazamine: from bench to clinical trials","volume":"1","author":"Marcu","year":"2006","journal-title":"Curr. Clin. Pharmacol."},{"issue":"55","key":"10.1016\/j.bcp.2026.117754_b0100","doi-asserted-by":"crossref","first-page":"8492","DOI":"10.1039\/C6CC02972H","article-title":"Hypoxia-responsive nanocarriers for cancer imaging and therapy: recent approaches and future perspectives","volume":"52","author":"Thambi","year":"2016","journal-title":"Chem. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.117754_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-12-152","article-title":"Tumor glycolysis as a target for cancer therapy: progress and prospects","volume":"12","author":"Ganapathy-Kanniappan","year":"2013","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0115","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.117754_b0120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"17","key":"10.1016\/j.bcp.2026.117754_b0125","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1002\/adma.201505869","article-title":"Light-activated hypoxia-responsive nanocarriers for enhanced anticancer therapy","volume":"28","author":"Qian","year":"2016","journal-title":"Adv. Mater. (Deerfield Beach, Fla.)"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0130","doi-asserted-by":"crossref","first-page":"39833","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0135","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201700097","article-title":"Cancer immunotherapy using CAR\u2010T cells: from the research bench to the assembly line","volume":"13","author":"Gomes-Silva","year":"2018","journal-title":"Biotechnol. J."},{"issue":"10","key":"10.1016\/j.bcp.2026.117754_b0140","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1080\/0284186X.2019.1629013","article-title":"Perfusion CT radiomics as potential prognostic biomarker in head and neck squamous cell carcinoma","volume":"58","author":"Bogowicz","year":"2019","journal-title":"Acta Oncol."},{"issue":"7781","key":"10.1016\/j.bcp.2026.117754_b0145","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/14737140.2021.1844007","article-title":"The role of the microbiome in drug resistance in gastrointestinal cancers","volume":"21","author":"Garajov\u00e1","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bcp.2026.117754_b0155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-3-030-91836-1_14","article-title":"Artificial intelligence for precision oncology","author":"Bhalla","year":"2022","journal-title":"Computational Methods for Precision Oncology"},{"key":"10.1016\/j.bcp.2026.117754_b0160","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jconrel.2023.07.015","article-title":"Gas-assisted phototherapy for cancer treatment","volume":"360","author":"Zhou","year":"2023","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.bcp.2026.117754_b0165","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/cells14090673","article-title":"The distinct role of HIF-1\u03b1 and HIF-2\u03b1 in hypoxia and angiogenesis","volume":"14","author":"Bakleh","year":"2025","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bcp.2026.117754_b0170","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0175","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/1874467215666220415131344","article-title":"Resveratrol augments doxorubicin and cisplatin chemotherapy: a novel therapeutic strategy","volume":"16","author":"Mirzaei","year":"2023","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117754_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115009","article-title":"Glycolysis-based drug delivery nanosystems for therapeutic use in tumors and applications","volume":"165","author":"Geng","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"14","key":"10.1016\/j.bcp.2026.117754_b0185","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/cells14141057","article-title":"Influence of hypoxia on tumor heterogeneity, DNA repair, and cancer therapy: from molecular insights to therapeutic strategies","volume":"14","author":"Kunachowicz","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0190","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.117754_b0195","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2502597122","article-title":"Tumor immune evasion: Systemic immunosuppressive networks beyond the local microenvironment","volume":"122","author":"Yan","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0200","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/ijms26041483","article-title":"Single-cell RNA sequencing in unraveling acquired resistance to EGFR-TKIs in non-small cell lung cancer: new perspectives","volume":"26","author":"Peng","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41568-024-00757-9","article-title":"Epigenomic heterogeneity as a source of tumour evolution","volume":"25","author":"Laisn\u00e9","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2026.117754_b0210","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/biology12091183","article-title":"From chaos to opportunity: decoding cancer heterogeneity for enhanced treatment strategies","volume":"12","author":"Ottaiano","year":"2023","journal-title":"Biology"},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0215","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2026.117754_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154711","article-title":"Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer","volume":"248","author":"Li","year":"2023","journal-title":"Pathol.-Res. Pract."},{"key":"10.1016\/j.bcp.2026.117754_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2025.104982","article-title":"Revisiting TAM polarization: beyond M1-and M2-type TAM toward clinical precision in macrophage-targeted therapy","volume":"143","author":"Wang","year":"2025","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.bcp.2026.117754_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114646","article-title":"The impact of hypoxia on tumor-mediated bypassing anti-PD-(L) 1 therapy","volume":"162","author":"Mortezaee","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41435-024-00315-1","article-title":"Hypoxia-induced autophagy in pancreatic cancer counteracts the cytotoxicity of CD8+ T cells by inhibiting the expression of MHC-I","volume":"26","author":"Zhou","year":"2025","journal-title":"Genes & Immunity"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0240","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.117754_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1040163","article-title":"Chronic inflammation, cancer development and immunotherapy","volume":"13","author":"Wen","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","article-title":"Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.117754_b0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1625114","article-title":"The role of inflammatory factors in the tumor microenvironment of pancreatic cancer","volume":"16","author":"Yuan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117754_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217350","article-title":"Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy","volume":"610","author":"Yu","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.117754_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115853","article-title":"Biology and function of exosomes in tumor immunotherapy","volume":"169","author":"Liu","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.bcp.2026.117754_b0270","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/biom15050685","article-title":"Exosome-mediated chemoresistance in cancers: mechanisms, therapeutic implications, and future directions","volume":"15","author":"Liu","year":"2025","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.bcp.2026.117754_b0275","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41568-024-00740-4","article-title":"CAF-induced physical constraints controlling T cell state and localization in solid tumours","volume":"24","author":"Arpinati","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.117754_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1340634","article-title":"Extracellular matrix remodeling in the tumor immunity","volume":"14","author":"Du","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117754_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.637675","article-title":"The role of tumor-stroma interactions in drug resistance within tumor microenvironment","volume":"9","author":"Ni","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-025-02675-8","article-title":"Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance","volume":"42","author":"Xiao","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bcp.2026.117754_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217116","article-title":"Natural products reverse cisplatin resistance in the hypoxic tumor microenvironment","volume":"598","author":"Yang","year":"2024","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0300","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.050542","article-title":"Stress in the metastatic journey\u2013the role of cell communication and clustering in breast cancer progression and treatment resistance","volume":"17","author":"Grasset","year":"2024","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.bcp.2026.117754_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1131874","article-title":"TME-targeted approaches of brain metastases and its clinical therapeutic evidence","volume":"14","author":"Khan","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0310","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12935-024-03518-8","article-title":"The axis of tumor-associated macrophages, extracellular matrix proteins, and cancer-associated fibroblasts in oncogenesis","volume":"24","author":"Yu","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.bcp.2026.117754_b0315","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/biology13060451","article-title":"The advancement and application of the single-cell transcriptome in biological and medical research","volume":"13","author":"Huang","year":"2024","journal-title":"Biology"},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0320","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1021\/acs.jproteome.4c00646","article-title":"Recent developments in single-cell metabolomics by mass spectrometry\u2500 a perspective","volume":"24","author":"Petrova","year":"2024","journal-title":"J. Proteome Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0325","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1002\/mog2.68","article-title":"Targets of tumor microenvironment for potential drug development","volume":"3","author":"Zhang","year":"2024","journal-title":"MedComm\u2013Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117754_b0330","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1039\/D4BM01677G","article-title":"Recent advances in non-invasive in vivo tracking of cell-based cancer immunotherapies","volume":"13","author":"Kulkarni","year":"2025","journal-title":"Biomater. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.117754_b0335","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","article-title":"Advances in PET imaging of cancer","volume":"23","author":"Schwenck","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0340","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3892\/ol.2024.14285","article-title":"Applications of single\u2011cell omics and spatial transcriptomics technologies in gastric cancer","volume":"27","author":"Ren","year":"2024","journal-title":"Oncol. Lett."},{"issue":"13","key":"10.1016\/j.bcp.2026.117754_b0345","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1177\/00220345241271934","article-title":"Spatial transcriptomics unravel the tissue complexity of oral pathogenesis","volume":"103","author":"Haller","year":"2024","journal-title":"J. Dent. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0350","doi-asserted-by":"crossref","first-page":"21","DOI":"10.55248\/gengpi.5.0224.0421","article-title":"AI-driven precision oncology: predictive biomarker discovery and personalized treatment optimization using genomic data","volume":"1","author":"Kumar","year":"2024","journal-title":"Int. J. Adv. Res. Publ. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2026.117754_b0355","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1039\/D2SC05709C","article-title":"AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor","volume":"14","author":"Ren","year":"2023","journal-title":"Chem. Sci."},{"issue":"D1","key":"10.1016\/j.bcp.2026.117754_b0360","doi-asserted-by":"crossref","first-page":"D395","DOI":"10.1093\/nar\/gkac1013","article-title":"GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources","volume":"51","author":"P\u00e1ndy-Szekeres","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0365","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12935-024-03621-w","article-title":"Organoids as a model system for researching human neuroendocrine tumor of the breast","volume":"24","author":"Zhao","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"7","key":"10.1016\/j.bcp.2026.117754_b0370","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s44222-024-00207-z","article-title":"Integrating organoids and organ-on-a-chip devices","volume":"2","author":"Zhao","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"issue":"5","key":"10.1016\/j.bcp.2026.117754_b0375","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41580-024-00804-1","article-title":"Modelling human brain development and disease with organoids","volume":"26","author":"Birtele","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.117754_b0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1353787","article-title":"Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy","volume":"15","author":"Nicolini","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0385","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s12010-024-05110-2","article-title":"Decoding drug discovery: exploring A-to-Z in silico methods for beginners","volume":"197","author":"Rasul","year":"2025","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.bcp.2026.117754_b0390","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1296341","article-title":"PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment","volume":"14","author":"Parvez","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0395","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/pharmaceutics15010049","article-title":"A guide to in silico drug design","volume":"15","author":"Chang","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0400","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/med.21886","article-title":"Targeting key proteins involved in transcriptional regulation for cancer therapy: current strategies and future prospective","volume":"42","author":"Pei","year":"2022","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0405","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10238-024-01501-1","article-title":"Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies","volume":"24","author":"Ciep\u0142a","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0410","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","article-title":"Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0415","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"14","key":"10.1016\/j.bcp.2026.117754_b0420","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/cells14141057","article-title":"Influence of hypoxia on tumor heterogeneity, DNA repair, and cancer therapy: from molecular insights to therapeutic strategies","volume":"14","author":"Dominika","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.117754_b0425","series-title":"Clinical Ophthalmic Oncology: Basic Principles","first-page":"51","article-title":"Cancer angiogenesis","author":"Joo","year":"2025"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0430","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13065-024-01135-0","article-title":"Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors","volume":"18","author":"Abdel-Mohsen","year":"2024","journal-title":"BMC Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0435","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12951-022-01394-w","article-title":"Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K\/mTOR inhibitor and resists HIF-1\u03b1-dependent tumor hypoxia adaptation","volume":"20","author":"Liu","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bcp.2026.117754_b0440","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.esmogo.2023.08.004","article-title":"Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC)","volume":"1","author":"van B\u00f6mmel","year":"2023","journal-title":"ESMO Gastrointest. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117754_b0445","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.3390\/molecules28124672","article-title":"Small molecule inhibitors as therapeutic agents targeting oncogenic fusion proteins: current status and clinical","volume":"28","author":"Kong","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0450","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.117754_b0455","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1571731","article-title":"Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type","volume":"16","author":"Oh","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117754_b0460","article-title":"Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0465","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/biomimetics8020146","article-title":"The extracellular matrix: its composition, function, remodeling, and role in tumorigenesis","volume":"8","author":"Dzobo","year":"2023","journal-title":"Biomimetics"},{"issue":"7","key":"10.1016\/j.bcp.2026.117754_b0470","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1021\/acs.molpharmaceut.5c00482","article-title":"Fibroblast activation protein as a molecular handle in cancer phototheranostics: recent advances","volume":"22","author":"Basak","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2026.117754_b0475","article-title":"Strategies for specific multimodal imaging of cancer-associated fibroblasts and applications in theranostics of cancer","volume":"30","author":"Wen","year":"2024","journal-title":"Mater. Today Bio"},{"issue":"6","key":"10.1016\/j.bcp.2026.117754_b0480","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3390\/cancers15061889","article-title":"Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.bcp.2026.117754_b0485","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.3390\/cancers14163906","article-title":"Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy","volume":"14","author":"Glabman","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2026.117754_b0490","article-title":"Based on small molecules: development and application of fibroblast activation protein inhibitors radiopharmaceutical in tumor precision therapy","volume":"16","author":"Luo","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117754_b0495","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12072-025-10788-5","article-title":"Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets","volume":"19","author":"Li","year":"2025","journal-title":"Hep. Intl."},{"key":"10.1016\/j.bcp.2026.117754_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2025.1585882","article-title":"Identification of novel potential hypoxia-inducible factor-1\u03b1 inhibitors through machine learning and computational simulations","volume":"13","author":"He","year":"2025","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0505","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13104-025-07133-2","article-title":"Naringenin-loaded nanoparticles modulate HIF-driven oxygen-sensing pathways in lung adenocarcinoma cells","volume":"18","author":"Ragab","year":"2025","journal-title":"BMC. Res. Notes"},{"issue":"35","key":"10.1016\/j.bcp.2026.117754_b0510","doi-asserted-by":"crossref","first-page":"39772","DOI":"10.1021\/acsomega.5c03503","article-title":"Novel sulfonamide derivatives as anticancer agents, VEGFR-2 inhibitors, and apoptosis triggers: design, synthesis, and computational studies","volume":"10","author":"Al-Ziyadi","year":"2025","journal-title":"ACS Omega"},{"issue":"5","key":"10.1016\/j.bcp.2026.117754_b0515","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1021\/acs.jmedchem.1c01682","article-title":"Discovery of small-molecule inhibitors of the PD-1\/PD-L1 axis that promote PD-L1 internalization and degradation","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2026.117754_b0520","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004695","article-title":"Therapeutic targeting of PD-1\/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment","volume":"10","author":"Ac\u00farcio","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.117754_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2022.107804","article-title":"Discovery of small-molecule PD-1\/PD-L1 antagonists through combined virtual screening and experimental validation","volume":"102","author":"DiFrancesco","year":"2023","journal-title":"Comput. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0530","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/ijms24021413","article-title":"Is the triggering of PD-L1 dimerization a potential mechanism for food-derived small molecules in cancer immunotherapy? A study by molecular dynamics","volume":"24","author":"Wu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.117754_b0535","article-title":"From laboratory to clinic: opportunities and challenges of functional food active ingredients in cancer therapy","volume":"12","author":"Zhang","year":"2025","journal-title":"Front. Nutr."},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0540","article-title":"Updates on glioblastoma multiforme: from epidemiology to imaging and artificial intelligence","volume":"6","author":"Bentourkia","year":"2025","journal-title":"Artif. Intell. Med. Imag."},{"issue":"5","key":"10.1016\/j.bcp.2026.117754_b0545","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40336-022-00523-7","article-title":"PET radiotracers in glioma: a review of clinical indications and evidence","volume":"10","author":"Castello","year":"2022","journal-title":"Clin. Transl. Imag."},{"issue":"12","key":"10.1016\/j.bcp.2026.117754_b0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278556","article-title":"A systematic review verified by bioinformatic analysis based on TCGA reveals week prognosis power of CAIX in renal cancer","volume":"17","author":"Zhang","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0555","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13046-024-03026-7","article-title":"Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation","volume":"43","author":"Ren","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.bcp.2026.117754_b0560","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.3390\/cancers16183129","article-title":"The role of ctdna and liquid biopsy in the diagnosis and monitoring of head and neck cancer: towards precision medicine","volume":"16","author":"Nassar","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2026.117754_b0565","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/9781119933861.ch13","article-title":"Hyperbaric oxygen therapy","author":"Braswell","year":"2024","journal-title":"Techniques in Small Animal Wound Management"},{"issue":"10","key":"10.1016\/j.bcp.2026.117754_b0570","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/ph17101389","article-title":"Targeting tumor hypoxia with nanoparticle-based therapies: challenges, opportunities, and clinical implications","volume":"17","author":"Debnath","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jkcvhl.v12i3.413","article-title":"Hypoxia inducible factor-2\u03b1 (HIF-2\u03b1) pathway inhibitors","volume":"12","author":"Dogra","year":"2025","journal-title":"J. Kidney Cancer VHL"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.117754_b0580","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/17512433.2024.2436433","article-title":"Targeting HIF-2\u03b1: the role of belzutifan in clear cell renal carcinoma management","volume":"18","author":"Vald\u00e9s","year":"2025","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117754_b0585","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.3390\/ijms25063313","article-title":"A molecular perspective on HIF-1\u03b1 and angiogenic stimulator networks and their role in solid tumors: an update","volume":"25","author":"Magar","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.bcp.2026.117754_b0590","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400127","article-title":"Recent development of transition metal complexes as chemotherapeutic hypoxia activated prodrug (HAP)","volume":"19","author":"Jagathesan","year":"2024","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/j.bcp.2026.117754_b0595","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/pol.20220702","article-title":"A novel hypoxia\u2010activated polymeric Tirapazamine derivative for enhanced antitumor therapy","volume":"61","author":"Xu","year":"2023","journal-title":"J. Polym. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2026.117754_b0600","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/molecules30102159","article-title":"Nitroxides: chemistry, antioxidant properties, and biomedical applications","volume":"30","author":"Gwozdzinski","year":"2025","journal-title":"Molecules"},{"issue":"34","key":"10.1016\/j.bcp.2026.117754_b0605","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202204629","article-title":"A multimodal therapeutic nanoplatform overcoming tumor hypoxia heterogeneity for improved tumor chemoradiotherapy","volume":"32","author":"Zhang","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.bcp.2026.117754_b0610","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2022.01.027","article-title":"HIF-1\u03b1 inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer","volume":"531","author":"Luo","year":"2022","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0615","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/antiox14010094","article-title":"Hypoxia-induced reactive oxygen species: their role in cancer resistance and emerging therapies to overcome it","volume":"14","author":"Mendoza","year":"2025","journal-title":"Antioxidants"},{"issue":"8","key":"10.1016\/j.bcp.2026.117754_b0620","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0625","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cllc.2022.12.003","article-title":"Comparison of chemotherapy plus pembrolizumab vs. chemotherapy alone in EGFR-mutant non\u2013small-cell lung cancer patients","volume":"24","author":"Chen","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0630","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jtho.2022.01.007","article-title":"The challenges of third-generation EGFR tyrosine kinase inhibitors in the therapy of advanced NSCLC","volume":"17","author":"Wang","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"27","key":"10.1016\/j.bcp.2026.117754_b0635","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1039\/D3RA02347H","article-title":"Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review","volume":"13","author":"Mansour","year":"2023","journal-title":"RSC Adv."},{"issue":"5","key":"10.1016\/j.bcp.2026.117754_b0640","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"14","key":"10.1016\/j.bcp.2026.117754_b0645","doi-asserted-by":"crossref","first-page":"11488","DOI":"10.1021\/acs.jmedchem.4c00113","article-title":"New horizons of synthetic lethality in cancer: current development and future perspectives","volume":"67","author":"Previtali","year":"2024","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2026.117754_b0650","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.3390\/molecules29122836","article-title":"Targeting NAD metabolism: rational design, synthesis and in vitro evaluation of NAMPT\/PARP1 dual-target inhibitors as anti-breast cancer agents","volume":"29","author":"Li","year":"2024","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0655","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/jmp6030020","article-title":"The future of cancer diagnosis and treatment: unlocking the power of biomarkers and personalized molecular-targeted therapies","volume":"6","author":"Molla","year":"2025","journal-title":"J. Mol. Pathol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0660","first-page":"1","article-title":"Artificial intelligence-driven integration of single-cell RNA sequencing and transcriptome analysis to decipher APOE\u2019s role in gastric cancer prognosis and therapy","volume":"16","author":"Li","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bcp.2026.117754_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125463","article-title":"siRNA-based therapeutics in hormone-driven cancers: advancements and benefits over conventional treatments","volume":"674","author":"Saha","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2026.117754_b0670","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241230869","article-title":"Adaptive control of tumor growth","volume":"31","author":"Derbal","year":"2024","journal-title":"Cancer Control"},{"issue":"10","key":"10.1016\/j.bcp.2026.117754_b0675","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.annonc.2023.08.008","article-title":"Treatment of evolving cancers will require dynamic decision support","volume":"34","author":"Strobl","year":"2023","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117754_b0680","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1002\/mco2.564","article-title":"Liquid biopsy for human cancer: cancer screening, monitoring, and treatment","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"issue":"8","key":"10.1016\/j.bcp.2026.117754_b0685","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/djad065","article-title":"Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy","volume":"115","author":"Mayerhofer","year":"2023","journal-title":"JNCI: J. Nat. Cancer Inst."},{"issue":"6","key":"10.1016\/j.bcp.2026.117754_b0690","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","article-title":"Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer","volume":"22","author":"Labrie","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.117754_b0695","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-biodatasci-102523-103801","article-title":"Harnessing artificial intelligence in multimodal omics data integration: paving the path for the next frontier in precision medicine","volume":"7","author":"Nam","year":"2024","journal-title":"Annu. Rev. Biomed. Data Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0700","first-page":"87","article-title":"AI-powered healthcare revolution: an extensive examination of innovative methods in cancer treatment","volume":"3","author":"Khan","year":"2024","journal-title":"BULLET: Jurnal Multidisiplin Ilmu"},{"issue":"7","key":"10.1016\/j.bcp.2026.117754_b0705","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1021\/acsomega.2c06659","article-title":"Mapping spatiotemporal heterogeneity in tumor profiles by integrating high-throughput imaging and omics analysis","volume":"8","author":"Patkulkar","year":"2023","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0710","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2026.117754_b0715","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1420920","article-title":"Immune checkpoint inhibitors targeting PD-1\/PD-L1 in the treatment of human lymphomas","volume":"14","author":"Ribatti","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.117754_b0720","doi-asserted-by":"crossref","unstructured":"M.A. Rodriguez, et al., Mechanism of action and pharmacologic features of drugs targeting PD\u20101\/PDL\u20101 and CTLA\u20104. Precision Cancer Therapies vol 2\u2010Immunologic Approaches for the Treatment of Lymphoid Malignancies\u2010From Concept to Practice, 2024: p. 139-155.","DOI":"10.1002\/9781119824572.ch11"},{"key":"10.1016\/j.bcp.2026.117754_b0725","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1573492","article-title":"PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution","volume":"16","author":"Kondo","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117754_b0730","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-med-080222-100847","article-title":"Application and expectations for immune checkpoint blockade of LAG3 and TIGIT","volume":"76","author":"Dumbrava","year":"2025","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bcp.2026.117754_b0735","article-title":"Current state of knowledge on the Immune checkpoint inhibitors in triple-negative breast cancer treatment: approaches, efficacy, and challenges","volume":"16","author":"Uchimiak","year":"2022","journal-title":"Clin. Med. Insights: Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117754_b0740","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.bcp.2026.117754_b0745","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.3390\/cancers14174160","article-title":"Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0750","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40364-024-00646-1","article-title":"Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomarker Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0755","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3390\/ijms25021205","article-title":"Extracellular vesicles and immunity: at the crossroads of cell communication","volume":"25","author":"Aloi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0760","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0765","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/pharmaceutics15041143","article-title":"Cancer resistance to immunotherapy: comprehensive insights with future perspectives","volume":"15","author":"Said","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0770","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0775","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s44222-023-00030-y","article-title":"Engineering cytokine therapeutics","volume":"1","author":"Deckers","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0780","first-page":"26","article-title":"Regulation of the activity of matrix metalloproteinases and their role in the body","volume":"2","author":"Sobirzhanovna","year":"2024","journal-title":"Web Med.: J. Med. Pract. Nurs."},{"key":"10.1016\/j.bcp.2026.117754_b0785","article-title":"Integrin signaling in tumor biology: mechanisms of intercellular crosstalk and emerging targeted therapies","volume":"13","author":"Li","year":"2025","journal-title":"PeerJ"},{"issue":"9","key":"10.1016\/j.bcp.2026.117754_b0790","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.3390\/ijms26094364","article-title":"Molecular mechanisms regulating epithelial mesenchymal transition (EMT) to promote cancer progression","volume":"26","author":"Ghafoor","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2026.117754_b0795","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/biology13050307","article-title":"Current landscape of cancer immunotherapy: harnessing the immune arsenal to overcome immune evasion","volume":"13","author":"Mitra","year":"2024","journal-title":"Biology"},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0800","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/jcm14020524","article-title":"Safety of cerebral intra-arterial chemotherapy for the treatment of malignant brain tumours","volume":"14","author":"Gahide","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2026.117754_b0805","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/9781119799627.ch23","article-title":"Radiofrequency and microwave thermal ablation in cancer therapy and the role of hydrodissection","author":"Chaturvedi","year":"2023","journal-title":"Application Heat Oncol. Principles Pract."},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0810","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/pharmaceutics17030296","article-title":"Advances in materials science for precision melanoma therapy: nanotechnology-enhanced drug delivery systems","volume":"17","author":"Moni","year":"2025","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.bcp.2026.117754_b0815","first-page":"160","article-title":"Protocol for stereotactic body radiation therapy: applications in oligometastases, radiation oncology, CT-simulation, immobilisation, and process quality control","volume":"2","author":"Al-Quraishi","year":"2024","journal-title":"Curr. Clin. Med. Educ."},{"issue":"5","key":"10.1016\/j.bcp.2026.117754_b0820","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3892\/etm.2024.12514","article-title":"Current clinical application of lutetium\u2011177 in solid tumors","volume":"27","author":"Niu","year":"2024","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117754_b0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2025.15088","article-title":"Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: a systematic review of current evidence and future prospects","volume":"30","author":"Ma","year":"2025","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-025-02641-4","article-title":"Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies","volume":"42","author":"Shah","year":"2025","journal-title":"Med. Oncol."},{"issue":"13","key":"10.1016\/j.bcp.2026.117754_b0835","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.3390\/ijms23136934","article-title":"Novel drugs with high efficacy against tumor angiogenesis","volume":"23","author":"Qi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.117754_b0840","unstructured":"K.C. McNeal, Investigating the effects of immune checkpoint inhibition and combined treatment with evofosfamide on the tumor microenvironment through hypoxia imaging. 2023: The University of Alabama at Birmingham."},{"key":"10.1016\/j.bcp.2026.117754_b0845","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1527600","article-title":"Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology","volume":"11","author":"Youssef","year":"2025","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0850","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/medicina61030385","article-title":"Hyperbaric oxygen therapy for managing cancer treatment complications: a safety evaluation","volume":"61","author":"Canarslan Demir","year":"2025","journal-title":"Medicina"},{"issue":"10","key":"10.1016\/j.bcp.2026.117754_b0855","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1007\/s12094-024-03449-w","article-title":"The effect of hyperbaric oxygen therapy in head and neck cancer patients with radiation induced dysphagia\u2014a systematic review","volume":"26","author":"Philipsen","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bcp.2026.117754_b0860","article-title":"Adverse effects of hyperbaric oxygen therapy: a systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2023","journal-title":"Front. Med."},{"issue":"7\u20139","key":"10.1016\/j.bcp.2026.117754_b0865","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/ars.2022.0118","article-title":"Evofosfamide and gemcitabine act synergistically in pancreatic cancer xenografts by dual action on tumor vasculature and inhibition of homologous recombination DNA repair","volume":"39","author":"Otowa","year":"2023","journal-title":"Antioxid. Redox Signal."},{"issue":"12","key":"10.1016\/j.bcp.2026.117754_b0870","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3390\/cancers17121988","article-title":"Evofosfamide enhances sensitivity of breast cancer cells to apoptosis and natural-killer-cell-mediated cytotoxicity under hypoxic conditions","volume":"17","author":"Das","year":"2025","journal-title":"Cancers"},{"issue":"33","key":"10.1016\/j.bcp.2026.117754_b0875","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034902","article-title":"Novel-fosfamide monotherapy or in combination with doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcoma: a pooled analysis of randomized clinical trials","volume":"102","author":"Liu","year":"2023","journal-title":"Medicine"},{"issue":"13","key":"10.1016\/j.bcp.2026.117754_b0880","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2005.05.2878","volume":"24","author":"Rischin","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117754_b0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0890","article-title":"Tumor hypoxia and radioresistance","volume":"48","author":"Morovi\u0107","year":"2024","journal-title":"Radiol. News Journal\/Radiolo\u0161ki Vjesnik"},{"key":"10.1016\/j.bcp.2026.117754_b0895","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.2147\/CMAR.S380857","article-title":"Considerations for the utility of real-world evidence beyond trial data in advanced NSCLC: the case of frontline tyrosine kinase inhibitors","volume":"14","author":"Gaitonde","year":"2022","journal-title":"Cancer Manag. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117754_b0900","first-page":"225","article-title":"Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review","volume":"17","author":"Khabbazpour","year":"2024","journal-title":"Gastroenterol. Hepatol. Bed to Bench"},{"issue":"7","key":"10.1016\/j.bcp.2026.117754_b0905","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1097\/JS9.0000000000001373","article-title":"Association between plasma circulating tumor DNA and the prognosis of esophageal cancer patients: a meta-analysis","volume":"110","author":"Zhang","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.bcp.2026.117754_b0910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ebiom.2022.104001","article-title":"Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis","volume":"79","author":"Xiao","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2026.117754_b0915","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baac030","article-title":"SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery","volume":"2022","author":"Wang","year":"2022","journal-title":"Database"},{"key":"10.1016\/j.bcp.2026.117754_b0920","doi-asserted-by":"crossref","DOI":"10.3389\/frai.2025.1624877","article-title":"From data-driven cities to data-driven tumors: dynamic digital twins for adaptive oncology","volume":"8","author":"Karaman","year":"2025","journal-title":"Front. Artif. Intell."},{"issue":"19","key":"10.1016\/j.bcp.2026.117754_b0925","doi-asserted-by":"crossref","first-page":"7814","DOI":"10.1039\/D5MH00501A","article-title":"Transforming surgical planning and procedures through the synergistic use of additive manufacturing, advanced materials and artificial intelligence: challenges and opportunities","volume":"12","author":"Tripathi","year":"2025","journal-title":"Mater. Horiz."},{"issue":"4","key":"10.1016\/j.bcp.2026.117754_b0930","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3390\/pharmaceutics15041240","article-title":"Safety and therapeutic optimization of lutetium-177 based radiopharmaceuticals","volume":"15","author":"Ladri\u00e8re","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.bcp.2026.117754_b0935","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1021\/acsabm.4c00819","article-title":"Prostate-specific membrane antigen-targeted NIR phototheranostics for prostate cancer","volume":"7","author":"Solanki","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"issue":"2","key":"10.1016\/j.bcp.2026.117754_b0940","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1021\/acsabm.4c01914","article-title":"Dual targeting of prostate-specific membrane antigen and fibroblast activation protein: bridging prostate cancer theranostics with precision","volume":"8","author":"Kumar","year":"2025","journal-title":"ACS Appl. Bio Mater."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:30:52Z","timestamp":1778056252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":188,"alternative-id":["S0006295226000857"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117754","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmasking the role of tumor microenvironment in the advanced stage of cancer treatment to mitigate risks during chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117754"}}